Skip to main content
Premium Trial:

Request an Annual Quote

PPO MultiPlan Covering GenomeDx's Prostate Cancer Test

NEW YORK (GenomeWeb) – Prostate cancer diagnostics firm GenomeDx today announced it has signed a contract with MultiPlan for diagnostic laboratory testing.

As result of the deal, members of the preferred provider organization will have access to GenomeDx's Decipher Prostate Cancer Classifier, which measures a patient's biological risk of developing metastatic prostate cancer. MultiPlan has more than 500,000 providers in its network.

In June, GenomeDx and Prime Health Services inked a deal providing coverage for Decipher, and more than 190 million covered lives now have access to GenomeDx's test, the San Diego-based company said.

Decipher uses whole-genome analysis to profile RNA expression signatures to measure the aggressiveness of prostate cancer in patients who have had a prostatectomy. The test provides information that is distinct from PSA information and other clinical risk factors.

The Scan

Panel Votes for COVID-19 Pill

A US Food and Drug Administration panel has voted to support the emergency use authorization of an antiviral pill for COVID-19 from Merck and Ridgeback Biotherapeutics, CNN says.

But Not Harm

New Scientist reports that UK bioethicists say that though gene editing may improve food production, it should not harm livestock welfare.

Effectiveness Drop Anticipated

Moderna's Stéphane Bancel predicts that that current SARS-CoV-2 vaccines may be less effective against the Omicron variant, the Financial Times reports.

Cell Studies of Human Chromatin Accessibility, SARS-CoV-2 Variants, Cell Signaling Networks

In Cell this week: chromatin accessibility maps of adult human tissues, modeling to track SARS-CoV-2 variants of concern, and more.